Biotech's Lawsuit With Eli Lilly Might Catalyze Stock
Source: Streetwise Reports (03/27/2024)
Nektar Therapeutics has commenced a Phase 2b clinical trial evaluating its lead product candidate rezpegaldesleukin in patients with severe to very severe alopecia areata. In other news, Nektar has a lawsuit pending against Eli Lilly & Co. Read on to see what two experts have to say about this biotech stock.
read more >
AI Co. Funded To Develop AI Approach to Health Equity
Source: Streetwise Reports (03/27/2024)
Treatment.com AI Inc. announced it has been granted funding from The National Institute of Health (NIH) to create a "culturally sensitive AI approach" when it comes to receiving familial medical histories for patients. Read on to see the medical need for this type of service and why one technical analysts is optimistic about this stock.
read more >
AI Medical App Passes Standard Student Test
Source: Streetwise Reports (03/26/2024)
This software is one of a suite offered by this health care technology firm. Learn about its other products and the growing sector.
read more >
Biotech Co.'s Target Price Significantly Higher Than Current
Source: Dr. Jonathan Aschoff (03/19/2024)
Biofrontera Inc. is currently trading at US$1.26, but has a target price of US$26, according to a Roth MKM research note.
read more >
Biotech Stocks Break Out
Source: Ron Struthers (03/19/2024)
Ron Struthers of Struthers Stock Report shares that the S&P Biotech SPDR is over 60% this year and trading around $100 a share. He also details how well he has down, buying under valued cash-rich biotechs in 2023, and shares one stock he believes it worth looking into.
read more >